Implications of the EMERALD Study for Patients, Providers, and Payers

The EMERALD study carries significant implications across multiple stakeholders in ER+/HER2- metastatic breast cancer. For patients, the trial highlights a new oral SERD option that can overcome endocrine resistance, particularly in those with ESR1 mutations, potentially extending disease control while maintaining a manageable safety profile. Providers benefit from evidence supporting biomarker-driven treatment decisions, enabling more personalized therapy sequencing and informed discussions around efficacy, tolerability, and prior therapy exposure. For payers, the study underscores the importance of cost-effective resource allocation, as targeted therapies and genomic testing may increase upfront expenditures but can improve outcomes and potentially reduce downstream healthcare utilization associated with disease progression.